In this clinical research, healthy individuals were given greater doses of OVX836, a recombinant influenza vaccine, to assess their safety and immunological response. A total of 137 people between the ages of 18 and 55 were enrolled and randomly randomized to receive a single intramuscular injection of either 180 g, 300 g, or 480 g of the OVX836 vaccine or placebo. The primary outcomes were the safety profile and the cell-mediated immune response as determined by IFN spot-producing cell frequencies on day 8 vs. baseline. The findings revealed that the three higher doses of the OVX836 vaccine were safe and generated dose-dependent cellular immune responses. further at the largest 480 g dosage tested, no maximum tolerated dose was attained, suggesting that further greater doses might potentially be effective.

To know more: About the original article click here.